The company aims to hire up to 50 people by the end of 2021 across disciplines of data science, machine learning, engineering, product management and computational biology.
"As Recursion continues to build a next-generation biopharma company, it's critical that we hire the best talent," said Co-Founder & CEO
Today, Recursion has over 260 employees across biology, chemistry, automation, data science, machine learning, engineering and accelerating functions. Over the past year, Recursion has increased its headcount by over 60 per cent. Through this growth, Recursion lived its values by helping all Recursionauts navigate the pandemic while safely keeping its labs open, secured a transformational discovery partnership with a major biopharmaceutical company and debuted on the public markets, all to accelerate the company's progress toward achieving its mission. Recursion has initiated the office selection process in
"As a proud Canadian who was born and raised in
Recursion has partnered with Toronto Global, a team of experienced business advisors assisting businesses around the globe expand into the
"I am thrilled to welcome Recursion to the
Candidates may learn more about Recursion and view open positions at Recursion.com/Careers.
About Recursion
Recursion is a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, machine learning and engineering. Our goal is to radically improve the lives of patients and industrialize drug discovery. Central to our mission is the Recursion Operating System, which combines an advanced infrastructure layer to generate what we believe is one of the world's largest and fastest-growing proprietary biological and chemical datasets. We combine that with the Recursion Map, a suite of custom software, algorithms and machine learning tools that we use to explore foundational biology unconstrained by human bias and navigate to new biological insights. Learn more at www.recursion.com, or connect on Twitter and LinkedIn.
Contact
Elyse.Freeman@Recursion.com
Investor Relations Contact
InvestorRelations@Recursion.com
Forward-Looking Statements
This press release contains information that includes or is based upon "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. Forward-looking statements provide our expectations or forecasts regarding future events. You can identify these statements by the fact they do not relate strictly to historical or current facts. They may use words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," and other terms of similar meaning in connection with a discussion of future operating or financial performance. In particular, forward-looking statements include statements relating to intended future actions; plans with respect to clinical trials and preclinical activities; prospective products or product approvals; future performance or results of anticipated products or technology; expenses; our ability to obtain, maintain and enforce intellectual property protections and financial results; in addition to other topics. Any or all of our forward-looking statements here or elsewhere may turn out to be wrong. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements and from expected or historical results. Many such factors will be important in determining our actual future results. Consequently, no forward-looking statement can be guaranteed. In particular, you should read the discussion in the "Risk Factors" section in our Prospectus filed with the
View original content to download multimedia:http://www.prnewswire.com/news-releases/recursion-announces-its-first-major-multidisciplinary-expansion-in-toronto-to-further-tech-enabled-drug-discovery-301311760.html
SOURCE Recursion
© Canada Newswire, source